Mohammad Hanan, Wahba Yahya, Gouida Mona, Shaltout Ali
1Genetic Unit, Pediatric Department, Faculty of Medicine, Mansoura University, Mansoura, 35516 Egypt.
2Section of Molecular Immunology, Mansoura University Children's Hospital, Mansoura, Egypt.
Indian J Hematol Blood Transfus. 2020 Jan;36(1):178-182. doi: 10.1007/s12288-019-01145-2. Epub 2019 Jun 5.
Cluster of differentiation 96 (CD96) is an important leukemic stem cells (LSCs) surface marker. We evaluated CD96 expression in children with acute leukemia (AL) and described its relation with treatment response. We conducted a prospective cohort study in Mansoura University Children's Hospital, Egypt during the period from 2014 to 2016. We studied 96 children with AL and 96 controls at clinical, laboratory and radiological levels. We assessed CD96% in LSCs using flow cytometry. AL group included 59 acute lymphoblastic leukemia (ALL) and 37 acute myeloid leukemia (AML) patients. ALL subgroup involved 44 B-ALL and 15 T-ALL patients while AML subgroup included 17 M2, 12 M4 and 8 M5 patients. CD96% was higher in AL group [57.63 (21.18-89.93)] than control [34.12 (16.15-39.51)] ( < 0.001). CD96% was higher in AML [68.25 (31.1-89.86)] than ALL [54.18 (21.18-89.93] ( < 0.001). CD96% in AML was M4 > M2 > M5 ( = 0.04) while within ALL subgroup, no significant difference was found between B-ALL and T-ALL ( = 0.807). CD96% in patients with non-complete remission was higher than those with complete remission ( = 0.004). CD96 is a reliable diagnostic marker for AL mainly AML and could be used as a prognostic marker for treatment response.
分化簇96（CD96）是一种重要的白血病干细胞（LSCs）表面标志物。我们评估了急性白血病（AL）患儿中CD96的表达情况，并描述了其与治疗反应的关系。2014年至2016年期间，我们在埃及曼苏拉大学儿童医院进行了一项前瞻性队列研究。我们在临床、实验室和放射学水平上研究了96例AL患儿和96例对照。我们使用流式细胞术评估LSCs中的CD96%。AL组包括59例急性淋巴细胞白血病（ALL）和37例急性髓系白血病（AML）患者。ALL亚组包括44例B-ALL和15例T-ALL患者，而AML亚组包括17例M2、12例M4和8例M5患者。AL组的CD96%[57.63（21.18 - 89.93）]高于对照组[34.12（16.15 - 39.51）]（<0.001）。AML组的CD96%[68.25（31.1 - 89.86）]高于ALL组[54.18（21.18 - 89.93]（<0.001）。AML中CD96%为M4>M2>M5（=0.04），而在ALL亚组中，B-ALL和T-ALL之间未发现显著差异（=0.807）。未完全缓解患者的CD96%高于完全缓解患者（=0.004）。CD96是AL主要是AML的可靠诊断标志物，可作为治疗反应的预后标志物。
